FOURIER

VIDEO: Prof Raul Santos: How can PCSK9 monoclonal antibody therapy be cost effective?

Prof Francois Mach: How will FOURIER impact guidelines

A landmark day for PCSK9 inhibition

What a landmark day for lipid lowering. All eyes were focused on FOURIER at the first of the late-breaking clinical trial sessions at ACC.2017. And the results didn’t disappoint. In patients with stable cardiovascular disease on maximally tolerated statin therapy, evolocumab treatment lowered LDL cholesterol…

Prof Henry Ginsberg: Data needed on the diabetes subgroup in FOURIER

Prof Philip Barter: How do we translate the FOURIER data to clinical practice?

Prof John Chapman: FOURIER – Why was there no significant effect on CV mortality?

Prof John Chapman: FOURIER endpoint data

Take home message on FOURIER

FOURIER: a landmark trial

Treatment with evolocumab on top of maximally tolerated statin led to significant reduction in the risk of major cardiovascular events, the primary study endpoint, by 15% (p<0.001), as well as a 20% reduction in the risk of the secondary ‘hard outcomes’ endpoint, a composite of…

PCSK9 Forum Editor Professor Henry Ginsberg discusses FOURIER

Countdown to FOURIER: What are the implications for patients?

Countdown to FOURIER: What are the implications for patients? PCSK9 Forum Editor Professor Anthony Wierzbicki gives his view.

Countdown to FOURIER: Are very low levels of LDL cholesterol safe?

A view from PCSK9 Forum Editor Dr Peter Lansberg (Academic Medical Center, Amsterdam, the Netherlands) Comment relates to: Giugliano RP, Wiviott SD, Blazing MA et al. Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol A Prespecified Analysis of the IMPROVE-IT…

Looking to FOURIER: What do the trials tell us about LDL lowering and cardiovascular events?

Presentation of full results from the FOURIER cardiovascular outcomes trial with the PCSK9 monoclonal antibody evolocumab is imminent. Here, PCSK9 Forum Editor Professor Anthony Wierzbicki (Guy’s and St Thomas’ NHS Foundation Trust, London UK) looks back over more than 25 years of trials of LDL…

FOURIER doesn’t disappoint: Amgen announces positive topline results

Amgen has confirmed that the much-awaited FOURIER (Further Cardiovascular OUtcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial showed that treatment with the PCSK9 inhibitor evolocumab significantly reduced the risk of cardiovascular events in patients with clinical atherosclerotic cardiovascular disease on optimized statin…